中华医学杂志(英文版)
中華醫學雜誌(英文版)
중화의학잡지(영문판)
CHINESE MEDICAL JOURNAL
2002年
10期
1552-1555
,共4页
吕枚%方佩华%张志友%何红鹏%高硕%侯秉璋%郑荣秀%肖茜%杨立平
呂枚%方珮華%張誌友%何紅鵬%高碩%侯秉璋%鄭榮秀%肖茜%楊立平
려매%방패화%장지우%하홍붕%고석%후병장%정영수%초천%양립평
可溶性细胞间粘附分子-1 放免法 单纯性甲肿 (简称SG) 格雷夫氏病(Graves'病,简称GD) 桥本氏病(Hashimoto'病,简称HT)
可溶性細胞間粘附分子-1 放免法 單純性甲腫 (簡稱SG) 格雷伕氏病(Graves'病,簡稱GD) 橋本氏病(Hashimoto'病,簡稱HT)
가용성세포간점부분자-1 방면법 단순성갑종 (간칭SG) 격뢰부씨병(Graves'병,간칭GD) 교본씨병(Hashimoto'병,간칭HT)
soluble intercellular adhesion molecule-1%radioimmunoassay%simple Goitre%Graves'disease%Hash imoto' thyroiditis
目的目前,国内外尚未见有关可溶性细胞间粘附分子-1(sICAM-1)放免法 (RIA)的报道,为此用本室研制的125Ⅰ-sICAM-1 RIA,检测正常人和三种甲状腺疾病(单纯性甲肿,Graves'病或Hashimoto'病)患者血清sICAM-1水平.方法用125Ⅰ-sICAM-1 RIA,检测400例正常人以及1020例患有单纯性甲状腺肿、Graves'病或者Hashimoto'病患者血清sICAM-1水平.结果正常组sICAM-1水平(±s)为:168.43±36.23 μg/L.正常组与单纯性甲肿组间无显著性差别(P>0.05),而自身免疫性甲状腺疾病(Graves'病和Hashimoto' 病)均分别明显高于正常组或单纯性甲肿组(P<0.05).三种治疗均可降低Graves' 病患者血清sICAM-1水平(P<0.05).药物治疗后甲状腺功能恢复正常的Graves'病组 sICAM-1水平明显低于Graves'病停药复发组(P<0.05).结论 125Ⅰ-sICAM-1 RIA可用于检测自身免疫性甲状腺疾病;血清sICAM-1水平可作为自身免疫性甲状腺疾病诊断的一个指标,及在评价Graves'病的疗效、停药或者复发等方面的一个指标.
目的目前,國內外尚未見有關可溶性細胞間粘附分子-1(sICAM-1)放免法 (RIA)的報道,為此用本室研製的125Ⅰ-sICAM-1 RIA,檢測正常人和三種甲狀腺疾病(單純性甲腫,Graves'病或Hashimoto'病)患者血清sICAM-1水平.方法用125Ⅰ-sICAM-1 RIA,檢測400例正常人以及1020例患有單純性甲狀腺腫、Graves'病或者Hashimoto'病患者血清sICAM-1水平.結果正常組sICAM-1水平(±s)為:168.43±36.23 μg/L.正常組與單純性甲腫組間無顯著性差彆(P>0.05),而自身免疫性甲狀腺疾病(Graves'病和Hashimoto' 病)均分彆明顯高于正常組或單純性甲腫組(P<0.05).三種治療均可降低Graves' 病患者血清sICAM-1水平(P<0.05).藥物治療後甲狀腺功能恢複正常的Graves'病組 sICAM-1水平明顯低于Graves'病停藥複髮組(P<0.05).結論 125Ⅰ-sICAM-1 RIA可用于檢測自身免疫性甲狀腺疾病;血清sICAM-1水平可作為自身免疫性甲狀腺疾病診斷的一箇指標,及在評價Graves'病的療效、停藥或者複髮等方麵的一箇指標.
목적목전,국내외상미견유관가용성세포간점부분자-1(sICAM-1)방면법 (RIA)적보도,위차용본실연제적125Ⅰ-sICAM-1 RIA,검측정상인화삼충갑상선질병(단순성갑종,Graves'병혹Hashimoto'병)환자혈청sICAM-1수평.방법용125Ⅰ-sICAM-1 RIA,검측400례정상인이급1020례환유단순성갑상선종、Graves'병혹자Hashimoto'병환자혈청sICAM-1수평.결과정상조sICAM-1수평(±s)위:168.43±36.23 μg/L.정상조여단순성갑종조간무현저성차별(P>0.05),이자신면역성갑상선질병(Graves'병화Hashimoto' 병)균분별명현고우정상조혹단순성갑종조(P<0.05).삼충치료균가강저Graves' 병환자혈청sICAM-1수평(P<0.05).약물치료후갑상선공능회복정상적Graves'병조 sICAM-1수평명현저우Graves'병정약복발조(P<0.05).결론 125Ⅰ-sICAM-1 RIA가용우검측자신면역성갑상선질병;혈청sICAM-1수평가작위자신면역성갑상선질병진단적일개지표,급재평개Graves'병적료효、정약혹자복발등방면적일개지표.
Objective To examine serum levels of sICAM-1 from normal controls and patients with thyroid diseases (simple goitre, Graves' disease or Hashimoto'sthyroiditis) with 125Ⅰ-sICAM-1 RIA established in our lab.Methods Using 125Ⅰ-sICAM-1 RIA, serum sICAM-1 levels of 400 healthy in dividuals as the normal group and 1020 patients with simple goitre (SG), Graves' disease (GD) or Hashimoto's thyroiditis (HT) were examined for a comporative chinical study.Conclusions sICAM-1 RIA can be used to examine autoimmune thyroid diseases. Serum levels of sICAM-1 can be used as a parameter in diagnosing autoimmune thyroid disease and in evaluating the effects of therapy, drug administration or relapse in GD.